Derivatives of pyrroloindole which are inhibitors of Hsp90, compositions containing same, and use thereof
View Patent ↗Pyrroloindoles of formula (I) are provided wherein Het is an aromatic or partially unsaturated, monocyclic or bicyclic heterocycle containing between 1 and 4 heteroatoms N, O or S, optionally substituted by R1 or R′1 which are the same or different; R is X-(A-B)n-CONH2, X-(A-B)n-O—CONH2, X-(A-B)n-NH—CONH2, X—(CH2)m-heterocycloalkyl, X(CH2)m-aryl and X—(CH2)m-heteroaryl wherein X is —O—C(O), —NH—C(O), NH—CS, —NH—CO—CH2-O—; —NH—COCH2-S—CH2-CO—NH—; —NH—CO—(CH2)2-SO2-; and —NH—CO—CH2-N(CH3)-CO—; A and B are the same or different and are each independently a single bond, CH2, CH-alkyl, and CH-aralkyl; n=1, 2 and m=0, 1; R1 and/or R′1 are H, halogen, CF3, nitro, cyano, alkyle, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, alkylthio, and carboxy, free or esterified by an alkyl, carboxamide, CONH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, and S(O2)-N(alkyl)2 group, all of said alkyl, alcoxy and alkylthio groups being optionally substituted themselves, said products being in all isomer forms and salts, as medicaments.
1. A compound according to formula (I)
in which:
Het represents a monocyclic or bicyclic, aromatic or partially unsaturated heterocycle—of dihydro or tetrahydro type—, with from 5 to 11 ring members, containing from 1 to 4 heteroatoms chosen from N, O or S, optionally substituted with one or more radicals R1 or R′1, which may be identical or different;
R is chosen from the group consisting of X-(A-B) n —CONH 2 , X-(A-B) n —O—CONH 2 , X-(A-B) n —NH—CONH 2 , X—(CH 2 ) m -heterocycloalkyl, X—(CH 2 ) m -aryl and X—(CH 2 ) m -heteroaryl where X represents —O—C(O), —NH—C(O), NH—CS, —NH—CO—CH 2 —O—; —NH—CO—CH 2 —S—CH 2 —CO—NH—; —NH—CO—(CH 2 ) 2 —SO 2 —; —NH—CO—CH 2 —N(CH 3 )—CO—; A and B, which may be identical or different, independently represent a single bond, CH 2 , CH-alkyl or CH-aralkyl, n=1 or 2 and m=0 or 1; and
R1 and R′1, which may be identical or different, are selected from the group consisting of H, halogen, CF 3 , nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, alkylthio, carboxyl in free form or esterified with an alkyl radical, carboxamide, CO—NH(alkyl), CON(alkyl) 2 , NH—CO-alkyl, sulphonamide, NH—SO 2 -alkyl, S(O) 2 —NHalkyl and S(O 2 )—N(alkyl) 2 , all the alkyl, alkoxy and alkylthio radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from halogen, hydroxyl, alkoxy, amino, alkylamino and dialkylamino;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 , in which:
Het is chosen from the group consisting of:
and
R1 and R′1, which may be identical or different, are selected from the group consisting of H, halogen, CF 3 , nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, alkylthio (methylthio), carboxyl in free form or esterified with an alkyl radical, carboxamide, CO—NH(alkyl) and CON(alkyl) 2 , NH—CO-alkyl, sulphonamide, NH—SO 2 -alkyl, S(O) 2 —NHalkyl and S(O 2 )—N(alkyl) 2 , all the alkyl, alkoxy and alkylthio radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from halogen, hydroxyl, alkoxy, amino, alkylamino and dialkylamino;
or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 2 , in which R is chosen from the group consisting of:
or a pharmaceutically acceptable salt thereof.
4. A compound according to claim 1 , in which:
Het is chosen from the group consisting of:
R is chosen from the group consisting of:
R1 is in the group consisting of H, F, Cl, Br, CF 3 , NO 2 , CN, CH 3 , OH, OCH 3 , OCF 3 , CO 2 Me, CONH 2 , CONHMe, CONH—(CH 2 ) 3 —OMe, CONH—(CH 2 ) 3 —N(Me) 2 , NHC(O)Me, SO 2 NH 2 and SO 2 N(Me) 2 ;
R′1 is in the group consisting of H, CONH 2 , CONHMe and OMe; and
R″1 is in the group consisting of F, Cl, OH, OMe, CN, O—(CH 2 ) 3 —OMe and O—(CH 2 ) 3 —N(Me) 2 ;
or a pharmaceutically acceptable salt thereof.
5. A compound according to claim 1 , in which:
Het is chosen from the group consisting of:
R is chosen from the group consisting of:
R1 is in the group consisting of H, F, Cl, Br, CF 3 , NO 2 , CN, CH 3 , OH, OCH 3 , OCF 3 , CO 2 Me, CONH 2 , CONHMe, CONH—(CH 2 ) 3 —OMe, CONH—(CH 2 ) 3 —N(Me) 2 , NHC(O)Me, SO 2 NH 2 and SO 2 N(Me) 2 ,
R′1 is in the group consisting of H, CONH 2 , CONHMe and OMe, and
R″1 is in the group consisting of F, Cl, OH, OMe, CN, O—(CH 2 ) 3 —OMe and O—(CH 2 ) 3 —N(Me) 2 ;
or a pharmaceutically acceptable salt thereof.
6. A compound according to claim 1 , in which:
Het is chosen from the group consisting of:
R1 represents H, F, Cl, Br, CF 3 , NO 2 , CN, CH 3 , OH, OCH 3 , OCF 3 , CO 2 Me, CONH 2 , CONHMe, CONH—(CH 2 ) 3 —OMe, CONH—(CH 2 ) 3 —N(Me) 2 , NHC(O)Me, SO 2 NH 2 or SO 2 N(Me) 2 ;
R′1 represents H, CONH 2 , CONHMe or OMe;
R″1 represents F, Cl, OH, OMe, CN, O—(CH 2 ) 3 —OMe or O—(CH 2 ) 3 —N(Me) 2 ; and
R is chosen from the group consisting of:
or a pharmaceutically acceptable salt thereof.
7. A compound selected from the group consisting of:
1H-pyrrolo[2,3-b]pyridine-4-carboxylic acid [5-(6-fluoro-1H-benzimidazol-2-yl)-9H-pyrrolo[1,2-a]indol-9-yl]amide;
1H-pyrrolo[2,3-b]pyridine-4-carboxylic acid (5-quinolin-3-yl-9H-pyrrolo[1,2-a]indol-9-yl)amide;
1H-pyrrolo[2,3-b]pyridine-4-carboxylic acid [5-(3H-imidazo[4,5-c]pyridin-2-yl)-9H-pyrrolo[1,2-a]indol-9-yl]amide; and
6-chloro-1H-pyrrolo[2,3-b]pyridine-4-carboxylicacid [5-(3H-imidazo[4,5-c]pyridin-2-yl)-9H-pyrrolo[1,2-a]indol-9-yl]amide;
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof.